Laktulose Mip Pharma

Lactulose, the active ingredient in Laktulose Mip Pharma, is an osmotic laxative presented as an oral solution for oral use. It is employed to relieve constipation and to reduce ammonia absorption in patients with hepatic encephalopathy, primarily in adult populations.

GNH USA supplies Laktulose Mip Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. This includes compliance with EU pharmacopeial specifications.

Laktulose Mip Pharma (lactulose) is used as an osmotic laxative to manage conditions related to impaired bowel motility and hepatic ammonia accumulation.

- Constipation: Relieves bowel transit delay and softens stools, facilitating easier defecation. - Hepatic encephalopathy: Lowers intestinal ammonia production, helping to improve neurocognitive symptoms in patients with liver disease. - Prevention of hepatic encephalopathy recurrence: Maintains low ammonia levels to reduce the risk of episodic decompensation.

Lactulose may cause a range of adverse reactions, most of which are mild and related to its laxative action.

Common Side Effects: - Abdominal bloating: Sensation of fullness or swelling in the abdomen. - Flatulence: Increased intestinal gas production. - Diarrhea: Loose, watery stools occurring more frequently. - Nausea: Feeling of queasiness or urge to vomit. - Stomach cramps: Intermittent abdominal pain or discomfort.

Serious or Rare Side Effects: - Severe electrolyte imbalance: Marked changes in sodium, potassium or other electrolytes. - Dehydration: Excess fluid loss leading to low blood volume. - Allergic reaction: Rash, itching, swelling or difficulty breathing. - Severe abdominal pain: Persistent, intense pain requiring medical attention.

Before initiating therapy with Laktulose Mip Pharma, consider the following precautions. - Dose adjustment: Tailor dose based on clinical response and stool frequency. - Fluid intake: Ensure adequate hydration to prevent dehydration. - Electrolyte monitoring: Monitor serum electrolytes in patients at risk of imbalance. - Renal impairment: Use with caution in patients with renal dysfunction. - Pregnancy and lactation: Safety not established; weigh benefits and risks. - Store at ambient temperature: Keep below 25°C in original container, protect from moisture.

Lactulose can interact with several medicines; awareness of the interaction level helps guide management.

Major Interactions (Avoid): - Antibiotics (e.g., rifaximin): May reduce lactulose efficacy by altering colonic flora. - Antidiarrheal agents (e.g., loperamide): Counteract lactulose’s laxative effect. - Mineral supplements (e.g., magnesium): May increase risk of electrolyte disturbances.

Moderate Interactions (Monitor Closely): - Diabetes medications: Lactulose can affect glucose absorption; monitor blood sugar. - Warfarin: Potential alteration of INR; monitor coagulation parameters. - Probiotics: May modify colonic metabolism; observe clinical response.